The findings showed that CD86 was highly expressed in most of the cancers, such as breast cancer, cholangiocarcinoma, colorectal cancer, esophageal cancer, glioma, renal clear cell carcinoma, renal papillary cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic cancer, rectal adenocarcinoma, gastric cancer, thyroid cancer, and endometrial cancer (Supplementary Figure 1). This evidence concerns the gene CD86 and colorectal cancer.